Jackson Laboratory and Broad Institute receive $34.5M ARPA-H award for pediatric epilepsy gene editing platform
The Jackson Laboratory (JAX), in partnership with the Broad Institute and other collaborators, has been selected for an up to $34.5 million ARPA-H THRIVE award to advance the Pediatric Epilepsies & Rare CNS (PERC) gene editing platform. The initiative aims to accelerate the development of in vivo precision genetic medicines for severe childhood neurologic diseases, including pediatric epilepsies and other rare central nervous system disorders. The multi-institutional project is led by the Broad Institute and funded through ARPA-H's Treating Hereditary Rare Diseases with In Vivo Precision Genetic Medicines program.
Key quotes
The Jackson Laboratory (JAX) today announced it has been selected, with the Broad Institute and other partners, for an up to $34.5 million contract from the Advanced Research Projects Agency for Health (ARPA-H)
PERC directly addresses the go
The funding will support the Pediatric Epilepsies & Rare CNS (PERC) gene editing platform, a bold, multi-institutional project led by the Broad Institute.
You might also wanna read
STAT+: ARPA-H launches $160 million effort to develop custom gene editing drugs
FDA Approves First Dual-AAV Gene Therapy for Genetic Hearing Loss Under Priority Voucher Program
The FDA has approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy for trea
FDA·2mo ago
FDA Clears NIH-Supported Gene Therapy MMA-101 for First Human Trial in Rare Metabolic Disorder
The FDA has cleared an Investigational New Drug (IND) application for MMA-101, an AAV-based gene therapy candidate developed with NIH suppor
ncats.nih.gov·9d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.